Psoriasis Patients Face Elevated Metabolic Syndrome Risk
Individuals with psoriasis are at a heightened risk of developing metabolic syndrome, according to recent research. This finding underscores the need for vigilant monitoring and proactive health management within this patient population.
Psoriasis as a MetS Risk Factor
A new study reveals that psoriasis significantly increases the likelihood of metabolic syndrome (MetS). The study further suggests that the severity of the psoriasis directly impacts the risk of MetS. The greater the inflammatory burden, the higher the metabolic disorder risk, as noted by the research.
Early recognition of MetS in psoriasis patients is critical for mitigating long-term health risks and improving clinical outcomes. Therefore, elucidating the relationship between the two can provide a basis for early clinical intervention and reduce the risk of comorbidities.
— World Today News (@worldtodaynews) June 16, 2025
“Early recognition of MetS in psoriasis patients is critical for mitigating long-term health risks and improving clinical outcomes,”
—Xiaoyan Zhang, China-Japan Friendship Hospital
According to the Centers for Disease Control and Prevention, roughly 37% of U.S. adults have metabolic syndrome, highlighting the broad public health relevance of this research (CDC, 2024).
Study Methodology
Researchers conducted a thorough analysis of studies on psoriasis and MetS. The investigation considered articles from databases like CNKI, PubMed, and Web of Science. The search encompassed publications up to February 2025, aiming to find all relevant studies.
The inclusion criteria for the analysis consisted of observational designs, such as cross-sectional and prospective studies. Studies needed to feature a psoriasis case group and a control group. Furthermore, the diagnosis had to be clinically or pathologically confirmed.
Key Findings
The meta-analysis included 14 articles involving 9,641 patients with psoriasis. The collective prevalence of clinically significant metabolic dysregulation among the psoriasis cases reached 26.49%. When compared to control groups, psoriasis patients showed higher odds ratios for MetS.
In patients with severe psoriasis, a higher risk of developing MetS was identified. The study revealed a positive linear trend between PASI scores and MetS incidence. This indicated a link between disease severity and the chances of developing MetS.
Call to Action
The investigators concluded that clinicians should pay closer attention to the metabolic health of psoriasis patients. Regular monitoring, alongside early intervention measures, is vital to prevent the onset of MetS. They emphasized the importance of interdisciplinary collaborations to improve patient care.
